What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025Blood

Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab

View Full Paper

Ask AI

Bookmark

Injection-site reactions in hemophilia A patients declined to less than 1% after 130 weeks.
Median duration of emicizumab treatment was 130.3 weeks, with 0.75% of over 42,000 injections linked to adverse events.
Exploratory analysis across four HAVEN studies assessed injection-site reactions in hemophilia A patients receiving prophylaxis.
Data shows these findings support the tolerability of emicizumab injections in diverse patient populations.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Exploratory analysis reveals declining injection-site reactions in hemophilia A patients receiving subcutaneous emicizumab, suggesting strong tolerability.

Cite This Study

Shannon L. Carpenter (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e102 https://doi.org/10.1182/blood-2025-4839

View Full Paper

Ask AI

Bookmark

Implication

Exploratory analysis reveals declining injection-site reactions in hemophilia A patients receiving subcutaneous emicizumab, suggesting strong tolerability.

Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab

Key Points

Discussion

Implication

Cite This Study

Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab

Key Points

Discussion

Implication

Cite This Study